Regulatory

Regulatory  ·  Weekly Digest - 14 February to 20 February 2026
ENHERTU Type II Variation Application validated in the EU as post-neoadjuvant treatment for patients with HER2 positive early breast cancer

Weekly Digest – February 2026 Weekly Digest – February 2026 19 February 2026: ENHERTU Type II Variation Application validated in the EU as post-neoadjuvant treatment for patients with HER2 positive early breast cancer The European Medicines Agency has validated a […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 14 February to 20 February 2026
Hengrui Medicine’s HER2 ADC, Trastuzumab Ruikang, has been included in the Breakthrough Therapy List for a new indication

Weekly Digest – February 2026 Weekly Digest – February 2026 14 February 2026: Hengrui Medicine’s HER2 ADC, Trastuzumab Ruikang, has been included in the Breakthrough Therapy List for a new indication Hengrui Medicine announced that its independently developed HER2-targeting antibody–drug […]

by Sandhya Ramalingam

Continue Reading